%0 Journal Article
%T Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
%A Ramzy GM
%A Norkin M
%A Koessler T
%A Voirol L
%A Tihy M
%A Hany D
%A McKee T
%A Ris F
%A Buchs N
%A Docquier M
%A Toso C
%A Rubbia-Brandt L
%A Bakalli G
%A Guerrier S
%A Huelsken J
%A Nowak-Sliwinska P
%J J Exp Clin Cancer Res
%V 42
%N 1
%D Apr 2023 3
%M 37013646
暂无%R 10.1186/s13046-023-02650-z
%X <B>BACKGROUND: </B>We propose a new approach for designing personalized treatment for colorectal cancer (CRC) patients, by combining ex vivo organoid efficacy testing with mathematical modeling of the results.<BR><B>METHODS: </B>The validated phenotypic approach called Therapeutically Guided Multidrug Optimization (TGMO) was used to identify four low-dose synergistic optimized drug combinations (ODC) in 3D human CRC models of cells that are either sensitive or resistant to first-line CRC chemotherapy (FOLFOXIRI). Our findings were obtained using second order linear regression and adaptive lasso.<BR><B>RESULTS: </B>The activity of all ODCs was validated on patient-derived organoids (PDO) from cases with either primary or metastatic CRC. The CRC material was molecularly characterized using whole-exome sequencing and RNAseq. In PDO from patients with liver metastases (stage IV) identified as CMS4/CRIS-A, our ODCs consisting of regorafenib [1 mM], vemurafenib [11 mM], palbociclib [1 mM] and lapatinib [0.5 mM] inhibited cell viability up to 88%, which significantly outperforms FOLFOXIRI administered at clinical doses. Furthermore, we identified patient-specific TGMO-based ODCs that outperform the efficacy of the current chemotherapy standard of care, FOLFOXIRI.<BR><B>CONCLUSIONS: </B>Our approach allows the optimization of patient-tailored synergistic multi-drug combinations within a clinically relevant timeframe.